Clinical trials: Respiratory Aspiration
Pulmonary Disease, Chronic Obstructive
Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone
A study to evaluate the effect of SB-656933-AAA on the body after a single dose in subjects who have been challenged with ozone.
- Trial name
- NCT00551811
- Testing
- SB-656933-AAA
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Cystic Fibrosis
Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
This is a study of multiple doses of inhaled QBW276 in patients with cystic fibrosis on top of standard of care. The study was divided into 3 Cohorts.
- Trial name
- NCT02566044
- Testing
- QBW276
- Where
- 4 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Astigmatism, Myopia
Effect of a Myopia Control Lens on the Astigmatism in Children
The goal of this clinical trial is to investigate over a one-year period the effect of myopia control spectacle lenses on astigmatism in children aged 6 to 13 years with myopia and astigmatism.
- Trial name
- MAC (NCT07810725)
- Testing
- Lenslet-based myopia control spectacle lens
- Volunteers
- 15 people
- Sponsor
- Essilor International
Cystic Fibrosis
Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution.
- Trial name
- ELITE (NCT00391976)
- Testing
- Tobramycin solution for inhalation 300 mg
- Volunteers
- 123 people
- Sponsor
- Novartis
Asthma
Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.
Comparison of two asthma treatments by lung function measures.
- Trial name
- NCT00370591
- Testing
- Salmeterol/fluticasone propionate and fluticasone propionate
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids
This is a randomized, double-blind, placebo controlled, four-arm, dose-ranging study. The purpose is to evaluate the relationship between the dose of lebrikizumab and the response in terms of the efficacy, safety, and…
- Trial name
- MOLLY (NCT00971035)
- Testing
- lebrikizumab (MILR1444A)
- Volunteers
- 210 people
- Sponsor
- Genentech, Inc.
Asthma
First Step With Singulair® Therapy (0476-323)
In adult patients with mild persistent asthma, singulair® 10 mg will be at least as effective as low dose Inhaled Corticosteroids (ICS) in improving asthma symptom control or satisfaction over a 6 week comparison period.
- Trial name
- FIRST (NCT00545324)
- Testing
- MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks, Comparator: Fluticasone / Duration of Treatment: 6 Weeks
- Volunteers
- 399 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea…
- Trial name
- NCT00662740
- Testing
- FDC tiotropium / salmeterol, Salmeterol, Tiotropium (Spiriva®)
- Where
- 72 sites in United States, Austria and 16 more
- Volunteers
- 220 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy…
- Trial name
- NCT01277523
- Testing
- tiotropium high dose, tiotropium low dose
- Where
- 69 sites in United States, Argentina and 12 more
- Volunteers
- 392 people
- Sponsor
- Boehringer Ingelheim
COPD
Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product as measured by increases in FEV1.
- Trial name
- NCT03480997
- Testing
- Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Pneuma Respiratory, Inc
Asthma
Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)
The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function, symptoms, and use of rescue medication in children with persistent asthma.
- Trial name
- NCT00163462
- Testing
- Ciclesonide
- Where
- 57 sites in Brazil, Germany and 4 more
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Respiratory Syncytial Virus Infections
Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections
To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.
- Trial name
- NCT06363370
- Testing
- Human interferon α1b Inhalation Solution
- Where
- China
- Volunteers
- 322 people
- Sponsor
- Kexing Biopharm Co., Ltd.
COVID-19, SARS-CoV 2
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)
The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by…
- Conditions
- COVID-19, SARS-CoV 2, Respiratory Disease, Pneumonia, Viral
- Trial name
- NCT04456088
- Testing
- 150 ppm Nitric Oxide delivered through LungFit Delivery System, 80 ppm Nitric Oxide delivered through LungFit Delivery System
- Sponsor
- Beyond Air Inc.
Asthma
Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
Primary objective To show the superiority of CHF 1535 (BDP/FF) pMDI (800/24 μg per day) over BDP HFA pMDI (800 μg per day) in terms of change from baseline to the entire treatment period in average pre-dose morning peak…
- Trial name
- FORCE (NCT01577082)
- Testing
- CHF1535 200/6 µg pMDI, BDP HFA 100 µg pMDI
- Where
- 66 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 542 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Respiratory Disorders
A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers
This will be a 3 part study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of GSK2862277 administered via inhalation (IH) or intravenous (IV) routes in healthy subjects.
- Trial name
- NCT01818024
- Testing
- Single IV dose of GSK2862277, Single IH dose of GSK2862277, Repeat IV dose of GSK2862277
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years…
- Trial name
- MITCHELL (NCT06644924)
- Testing
- Intervention: AS MDI, Intervention: Ventolin Evohaler
- Where
- 22 sites in United States
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
Covid19
A Clinical Study Evaluating Inhaled Aviptadil on COVID-19
This study is a multicenter, prospective, placebo-controlled, comparative, randomized, double-blind local phase II clinical trial. Duration of study is 18 months.
- Trial name
- HOPE (NCT04844580)
- Testing
- Inhaled Aviptadil
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Centurion Pharma
Diabetes Mellitus, Type 2
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
To compare efficacy and safety of Exubera® vs Lantus® in patients with type 2 diabetes mellitus.
- Trial name
- NCT00391027
- Testing
- Insulin Glargine (Lantus®), Inhaled Human Insulin (Exubera®)
- Where
- 62 sites in Belgium, Finland and 8 more
- Volunteers
- 261 people
- Sponsor
- Pfizer
Asthma
Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler
The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbuhaler in terms of the drug absorbed into the bloodstream.
- Trial name
- NCT01593826
- Testing
- Charcoal and Budesonide/formoterol Easyhaler 320/9 microg, Charcoal and Symbicort Turbuhaler, Budesonide/formoterol Easyhaler 320/9 microg
- Where
- Finland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®
The purpose of this study is to describe the use of rescue medication and quality of life in adult asthmatic patients, either treated with SYMBICORT SMART® (regular dose according to physician's prescription and the current…
- Trial name
- NCT00884689
- Where
- 43 sites in Germany
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.